Tianjin Tanabe Seiyaku Co., Ltd.
Tianjin Tanabe Seiyaku Co., Ltd. was jointly funded and established by Tianjin Lisheng Pharmaceutical Co., Ltd. (formerly Tianjin Lisheng Pharmaceutical Factory) and Japan Tanabe Seiyaku Mitsubishi Pharmaceutical Co., Ltd. (formerly Tanabe Seiyaku Co., Ltd.), and officially started its operation in November 1994. The Company has a registered capital of USD 16.23 million, a coverage of 53,200 square meters, and an annual production capacity of 900 million tablets. At present, the Company has ten drug products, among which the cerebrovascular drugs include Hexinshuang Tablets, Hebeishuang Capsules, Hebeishuang Injections, Dashuang, ANPLAG, NOVASTAN, and so on, and the digestive system drugs include Shuli Qineng, Gaishuang, and so on. In 2019, the Company’s sales revenue reached RMB 364 million.